Induction of virus-specific T-cell responses in mucosal as well as systemic compartments of the immune system is likely to be a critical feature of an effective AIDS vaccine. We investigated whether virus-specific CD8 ؉ lymphocytes induced in rhesus macaques by immunization with attenuated simian immunodeficiency virus (SIV), an approach that is highly effective in eliciting protection against mucosal challenge, express the mucosa-homing receptor ␣4␤7 and traffic to the intestinal mucosa. SIV-specific CD8 ؉ T cells expressing ␣4␤7 were detected in peripheral blood and intestine of macaques infected with attenuated SIV. In contrast, virusspecific T cells in blood of animals immunized cutaneously by a combined DNA-modified vaccinia virus Ankara regimen did not express ␣4␤7. These results demonstrate the selective induction of SIV-specific CD8 ؉ T lymphocytes expressing ␣4␤7 by a vaccine approach that replicates in mucosal tissue and suggest that induction of virus-specific lymphocytes that are able to home to mucosal sites may be an important characteristic of a successful AIDS vaccine.
Induction of virus-specific T-cell responses in mucosal as well as systemic compartments of the immune system is likely to be a critical feature of an effective AIDS vaccine. We investigated whether virus-specific CD8
؉ lymphocytes induced in rhesus macaques by immunization with attenuated simian immunodeficiency virus (SIV), an approach that is highly effective in eliciting protection against mucosal challenge, express the mucosa-homing receptor ␣4␤7 and traffic to the intestinal mucosa. SIV-specific CD8
؉ T cells expressing ␣4␤7 were detected in peripheral blood and intestine of macaques infected with attenuated SIV. In contrast, virusspecific T cells in blood of animals immunized cutaneously by a combined DNA-modified vaccinia virus Ankara regimen did not express ␣4␤7. These results demonstrate the selective induction of SIV-specific CD8 ؉ T lymphocytes expressing ␣4␤7 by a vaccine approach that replicates in mucosal tissue and suggest that induction of virus-specific lymphocytes that are able to home to mucosal sites may be an important characteristic of a successful AIDS vaccine.
Transmission of human immunodeficiency virus (HIV) infection occurs predominantly across genital or rectal mucosal surfaces. Following viral dissemination, the large pool of activated CD4
ϩ T cells that reside in gut-associated lymphoid tissue (GALT) serves as a predominant site of HIV or simian immunodeficiency virus (SIV) replication (25, 26, 28) . Thus, the ability of virus-specific immune responses to prevent or contain HIV or SIV replication in mucosal sites is likely to play a critical role in the ability of the host to defend itself against lentiviral infection.
The mucosal immune system is functionally and phenotypically distinct from the peripheral immune system (3, 20) . Induction of immune responses by peripheral immunization at cutaneous or intramuscular sites results in antigen-specific lymphocytes that do not efficiently traffic to mucosal sites (3, 20) . Homing of lymphocytes to cutaneous or mucosal sites is determined in part by expression of cell surface adhesion molecules (5). The intestinal homing receptor ␣4␤7 plays a central role in directing migration of lymphocytes into intestinal mucosal tissue (30) . Lymphocytes expressing ␣4␤7 bind to the mucosal addressin MAdCAM-1, which is selectively expressed on capillary endothelium in gastrointestinal immune inductive and effector sites (4, 12) .
Despite evidence for the compartmentalization of peripheral and mucosal immune systems, little information is available on the ability of different AIDS vaccine strategies to induce cytotoxic T lymphocytes (CTL) that are able to home to mucosal sites. HIV-1 and SIV-specific CTL have been detected in genital and gastrointestinal mucosal tissues following infection with pathogenic viruses (8, 19, 21, 22) . However, there has been little or no information on the ability of candidate AIDS vaccines to induce cellular immune responses at mucosal sites. In this study, we asked whether CD8 ϩ T cells induced in macaques by immunization with attenuated SIV express the intestinal homing receptor ␣4␤7 and home to gastrointestinal lymphoid tissue. Induction of ␣4␤7 ϩ virus-specific CD8 ϩ T cells was also investigated in monkeys that were immunized cutaneously with a combined DNA-modified vaccinia virus Ankara strain vaccine expressing an immunodominant SIV CTL epitope.
In general, induction of memory lymphocytes expressing ␣4␤7 requires viral infection at gastrointestinal sites and is not observed with infection at extraintestinal sites (24) . However, because replication of attenuated SIV occurs preferentially in the pool of activated CD4 ϩ T lymphocytes found in GALT, even following intravenous infection (28), we reasoned that macaques intravenously infected with attenuated SIV would have SIV-specific CD8 ϩ T cells that express ␣4␤7. To address this hypothesis, we studied adult rhesus macaques infected intravenously with either SIVmac239⌬nef, containing a 182-bp deletion in nef (17) , or SIVmac293⌬3, which contains deletions in nef, vpr, and upstream short sequences of the long terminal repeat (31) 5 to 10 years after infection. Two of these animals, 353.88 and 71.88, had been challenged intravenously with pathogenic SIVmac239 or SIVmac251 3 to 7 years earlier; none of the monkeys exhibited evidence of infection with pathogenic virus at the time of this study (10, 31) . SIV-specific CD8 ϩ T cells were identified by multiparameter flow cytometry using tetramers of the rhesus major histocompatibility complex (MHC) class I molecule Mamu-A*01 complexed with the immunodominant Gag peptide p11C,C3M (CTPYDI NQM) (1, 13) . Tetramers were prepared from purified monomers by the gradual addition over 24 h of a allophycocya-nin (APC)-streptavidin (Molecular Probes) to a 4:1 final molar ratio. Four monkeys were identified as expressing Mamu-A*01 using the PCR SSP as previously described (18) . Immunofluorescent staining was performed on Ficoll-Hypaque-isolated peripheral blood mononuclear cells (PBMC) or whole blood using Mamu-A*01-peptide tetramers and anti-␣4␤7 antibody (a gift from LeukoSite, Inc.) on a FACSCalibur flow cytometer (Becton Dickinson). Four-color analysis of CD3 ϩ CD8 ϩ gated lymphocytes revealed between 0.28 and 0.95% tetramer-binding cells in peripheral blood of live attenuated SIV-immunized monkeys ( Fig. 1A and Table 1 ). Two monkeys infected with wild-type SIV (SIVmac239) had 0.93 and 0.32% tetramerbinding CD8 ϩ T cells (Fig. 1B and Table 1 ). Simultaneous analysis of tetramer binding and expression of ␣4␤7 revealed that between 36 and 84% of SIV-specific CD8 ϩ T cells in animals vaccinated with live attenuated SIV expressed ␣4␤7, a frequency generally similar to the level of expression on all CD3 ϩ CD8 ϩ T cells. A comparable percentage of tetramer binding cells in wild-type SIV-infected animals expressed ␣4␤7. These findings support the conclusion that replication of attenuated SIV in intestinal lymphoid tissue results in a virusspecific CD8
ϩ T cell response that is capable of intestinal homing. These results are also consistent with a previous report describing expression of ␣4␤7 by circulating T cells recognizing rotavirus, a pathogen for which replication is generally restricted to the small intestine (24) .
In order to examine whether induction of ␣4␤7 ϩ SIV-specific CD8 ϩ T cells necessarily requires antigen presentation in gastrointestinal tissue, we examined the phenotype of SIVspecific CD8 ϩ T cells induced by cutaneous immunization with DNA and modified vaccinia virus Ankara (MVA). Three Mamu-A*01-positive macaques were immunized with a multiepitope gene using a DNA prime-MVA boost regimen as described previously, which has been shown to induce p11C,C3 M-specific CTL in peripheral blood of immunized macaques (2, 14) . The DNA vaccine was administered to the skin on five occasions using the Dermal PowderJect XR "gene gun" (PowderJect Vaccines, Madison, Wis.), followed by two boosts with MVA delivered intradermally. Cutaneous immunization with MVA results in localized expression of viral antigens, since MVA infects but does not replicate in mammalian cells (27) , and thus tetramer-positive CD8 ϩ T cells induced by immunization with DNA-MVA would be expected to be negative for ␣4␤7. We therefore examined blood from DNA-MVA-immunized monkeys for tetramer binding and ␣4␤7 expression. In contrast to CD8 ϩ T cells from monkeys infected with attenuated SIV, tetramer-binding cells induced by the DNA-MVA vaccine regimen 1 week after a cutaneous MVA boost did not express ␣4␤7 (Fig. 1C) . Similar results were observed at 2 and 3 weeks after MVA boosting (data not shown). These results suggest that antigen-specific T cells induced by cutaneous immunization with vaccines that do not disseminate to GALT are unlikely to express ␣4␤7, a conclusion supported by the prior observation that memory T cells induced by peripheral immunization with an attenuated mumps vaccine did not express ␣4␤7 (24) . However, the DNA-MVA-and attenuated SIVvaccinated animals may differ in several respects, including the degree of T-cell activation and the presence of T-cell help, and further studies with expanded numbers of vaccinated animals will be necessary to document whether expression of ␣4␤7 on antigen-specific T cells is necessarily induced only by antigen presentation in GALT.
Having established that attenuated SIV immunization elicits ␣4␤7 ϩ SIV-Gag-specific CTL in peripheral blood, we investigated whether cells with this phenotype were able to home to gastrointestinal mucosal sites. Lymphocytes were isolated from endoscope-guided pinch biopsies of duodenum and colon and excisional biopsies of peripheral lymph node from four macaques immunized with attenuated SIV, and the cells were analyzed for expression of ␣4␤7 and tetramer binding. Cells were isolated from intestinal tissues using a combination of mechanical and enzymatic dissociation procedures described elsewhere (29) . Lymphocyte populations isolated using this procedure include a mixture of intraepithelial and lamina propria lymphocytes. SIV-specific CD8 ϩ T cells were detected in peripheral lymph nodes and in both intestinal sites of all four animals. Three of four monkeys exhibited increases of 2-to 20-fold in tetramer-binding cells in one or both intestinal sites
FIG. 2. SIV-specific CD8
ϩ T cells in attenuated SIV-immunized macaques home to intestinal mucosa and express ␣4␤7. Cells were isolated from fresh biopsy specimens, stained and analyzed by flow cytometry for tetramer binding and ␣4␤7 expression on CD3 ϩ CD8 ϩ lymphocytes. A minimum of 100,000 events were collected for each analysis. compared to levels in peripheral blood (Table 2 and Fig. 2 ). Higher percentages of tetramer-binding cells were also found in peripheral lymph nodes relative to levels in blood in two out of three animals. At least 50% of tetramer-binding cells in duodenum, colon, and lymph node expressed ␣4␤7, a similar proportion to that observed in peripheral blood. As expected, the total CD3 ϩ CD8 ϩ lymphocyte population in duodenum and colon were enriched for ␣4␤7 ϩ cells compared to these populations in peripheral blood and lymph node ( Table 2) .
The ability of virus-specific T cells to home to mucosal sites of viral replication plays a critical role in their ability to control viral replication. Evidence for the importance of mucosal homing can be found in pulmonary influenza virus infection, where the ability of adoptively transferred CD8 ϩ T cells to migrate to the site of infection is critical for protection (6) . This also appears to be the case in intestinal rotavirus infection, where viral clearance has been correlated with induction of virusspecific CD8 ϩ T cells expressing ␣4␤7 (23) . Similarly, subcutaneous immunization of mice with an HIV peptide immunogen induced systemic but not mucosal CTL and failed to protect mice against rectal challenge with a recombinant vaccinia virus expressing the HIV-1 envelope, whereas rectal immunization induced both mucosal and systemic CTL and protection against mucosal challenge (3). It is probable that mucosal homing will prove to also be important for protection against HIV and SIV infection. While the DNA prime-MVA boost vaccination regimen (14) , as well as several other HIV vaccine approaches (7, 11) , are effective at inducing virusspecific CD8 ϩ T cells, no information is presently available regarding the mucosal homing ability of cells induced by these vaccines, and little is known about their protective effects. Our recent results suggest that virus-specific CD8 ϩ T cells induced by the DNA-MVA vaccine may not be able to traffic to the intestine, possibly rendering this approach less effective in inducing protection against SIV or HIV infection. Consistent with this hypothesis, an initial report examining the ability of a cutaneous DNA-MVA vaccination regimen to protect against rectal SIV challenge failed to observe protection in two of three animals studied, despite the fact that levels of tetramerbinding cells at the time of challenge ranged from 1 to 5% of CD8 ϩ T cells in peripheral blood (14) , a level approximately two-to fivefold greater than we observed in animals vaccinated with attenuated SIV. In contrast, attenuated SIV immunization has previously been shown to protect against rectal and vaginal SIV challenge (9, 16) .
In summary, our results indicate that virus-specific CD8 ϩ T cells are induced by immunization with attenuated SIV express ␣4␤7 and home to mucosal sites, whereas those induced by a DNA-MVA vaccine lack expression of the intestinal homing receptor. Since induction of virus-specific immune responses in mucosal sites is likely to be a critical component of an effective AIDS vaccine, these findings may have important implications for future vaccine design.
All animals were maintained in accordance with the Guide for the Care and Use of Laboratory Animals (15) and institutional animal use committee guidelines.
